Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Admits To Knowingly Obstructing FDA Inspection In Guilty Pleas On Levothroid, Celexa Marketing

This article was originally published in The Pink Sheet Daily

Executive Summary

Forest Pharmaceuticals reached a $313 million settlement with the Department of Justice to resolve criminal charges of obstructing an FDA inspection and distributing a misbranded drug and civil False Claims Act allegations.
Advertisement

Related Content

Forest COPD Combo Hits Roadblock En Route To NDA Filing
Forest COPD Combo Hits Roadblock En Route To NDA Filing
Forest COPD Combo Hits Roadblock En Route To NDA Filing
Daliresp Sales Pitch Draws FDA Letter After Forest Fails To Heed Advisory Comments
HHS Office of Inspector General Drops Challenge To Forest CEO Solomon
Icahn Is Forest’s Latest Wolf At The Door
Could Forest's DDMAC Letter For Off-Label Promotion Doom CEO Solomon?
How Broadly Will OIG Enforce Its Exclusion Powers? Possible Action Against Forest CEO Offers A Lesson
DoJ Expanding False Claims Cases Into New Areas Left Before To FDA
Qui Tam Litigation: Peter Rost Suit Fails As Others Thrive

Topics

Advertisement
UsernamePublicRestriction

Register

PS071175

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel